GLP-1 responses are heritable and blunted in acquired obesity with high liver fat and insulin resistance

Diabetes Care

Volumn 37, Issue 1, 2014, Pages 242-251

  Matikainen, Niina ^a,b   Bogl, Leonie H ^a   Hakkarainen, Antti ^b   Lundbom, Jesper ^b   Lundbom, Nina ^b   Kaprio, Jaakko ^a,c   Rissanen, Aila ^a,b   Holst, Jens J ^d   Pietiláinen, Kirsi H ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d Capital Region   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; PEPTIDE YY; PEPTIDE YY [3-36]; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE BLOOD LEVEL; PEPTIDE FRAGMENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CONTROLLED STUDY; DIZYGOTIC TWINS; ENVIRONMENTAL FACTOR; FAT CONTENT; FEMALE; GENETIC VARIABILITY; HERITABILITY; HUMAN; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIVER CELL; LIVER FAT; MALE; MONOZYGOTIC TWINS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; TEST MEAL; TWIN DISCORDANCE; BLOOD; BODY WEIGHT; GENETICS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; LIPID METABOLISM; LIVER; METABOLISM; TWINS;

ADULT; BLOOD GLUCOSE; BODY WEIGHT; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HUMANS; INCRETINS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; MALE; OBESITY; PEPTIDE FRAGMENTS;

EID: 84892380456     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-1283     Document Type: Article

References (38)

1. Meier JJ. The contribution of incretin hormones to the pathogenesis of type 2 diabetes. Best Pract Res Clin Endocrinol Metab 2009;23:433-441
2. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (noninsulin-dependent) diabetes. Diabetologia 1986;29:46-52
3. Speliotes EK, Willer CJ, Berndt SI, et al.; MAGIC; Procardis Consortium. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 2010;42:937-948
4. Saxena R, Hivert MF, Langenberg C, et al.; GIANT consortium; MAGIC investigators. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 2010;42:142-148
5. Nauck M, Hahn S, Sauerwald A, Schmiegel W. Lack of germline mutations in the preproglucagon gene region coding for glucagon-like peptide 1 in type 2 diabetic (NIDDM) patients. Exp Clin Endocrinol Diabetes 2000;108:72-75
6. Mussig K, Staiger H,Machicao F, Haring HU, Fritsche A. Genetic variants affecting incretin sensitivity and incretin secretion. Diabetologia 2010;53:2289-2297
7. Yeung EH, Zhang C, Chen J, et al. Polymorphisms in the neuropeptide Y gene and the risk of obesity: Findings from two prospective cohorts. J Clin Endocrinol Metab 2011;96:E2055-E2062
8. Campbell CD, Lyon HN, Nemesh J, et al. Association studies of BMI and type 2 diabetes in the neuropeptide Y pathway: A possible role for NPY2R as a candidate gene for type 2 diabetes in men. Diabetes 2007;56:1460-1467
9. Van Dongen J, Slagboom PE, Draisma HH, Martin NG, Boomsma DI. The continuing value of twin studies in the omics era. Nat Rev Genet 2012;13:640-653
10. Kaprio J. Twin studies in Finland 2006. Twin Res Hum Genet 2006;9:772-777
11. Tyynismaa H, Raivio T, Hakkarainen A, et al. Liver fat but not other adiposity measures influence circulating FGF21 levels in healthy young adult twins. J Clin Endocrinol Metab 2011;96:E351-E355
12. Grańer M, Seppala-Lindroos A, Rissanen A, et al. Epicardial fat, cardiac dimensions, and low-grade inflammation in young adult monozygotic twins discordant for obesity. Am J Cardiol 2012;109:1295-1302
13. Lundbom J, Hakkarainen A, Fielding B, et al. Characterizing human adipose tissue lipids by long echo time 1H-MRS in vivo at 1.5 Tesla: Validation by gas chromatography. NMR Biomed 2010;23:466-472
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419
15. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: Comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470
16. Krarup T, Madsbad S, Moody AJ, et al. Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulindependent) diabetics. J Clin Endocrinol Metab 1983;56:1306-1312
17. Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycineextended glucagon-like peptide I in humans. Diabetes 1994;43:535-539
18. Neale MC, Boker SM, Xie G, Maes HH. Mx: Statistical Modeling. 6th ed. Richmond, VA, Virginia Commonwealth University Department of Psychiatry, 2003
19. Falconer DS, Mackay TFC. Introduction to Quantitative Genetics. 4th ed. Harlow, Essex, UK, Longmans Green, 1996
20. Neale MC, Cardon LR. Methodology for Genetic Studies of Twins and Families. Dordrecht, The Netherlands, Kluwer Academic Publications, 1992
21. Knop FK, Aaboe K, Vilsbøll T, et al. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab 2012;14:500-510
22. Schousboe K, Visscher PM, Henriksen JE, Hopper JL, Sørensen TI, Kyvik KO. Twin study of genetic and environmental influences on glucose tolerance and indices of insulin sensitivity and secretion. Diabetologia 2003;46:1276-1283
23. SalehiM, Aulinger B, DAlessio DA. Effect of glycemia on plasma incretins and the incretin effect during oral glucose tolerance test. Diabetes 2012;61:2728-2733
24. Nauck MA, El-Ouaghlidi A, Gabrys B, et al. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regul Pept 2004;122:209-217
25. Meier JJ, Gallwitz B, Askenas M, et al. Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes. Diabetologia 2005;48: 1872-1881
26. Vaag AA, Holst JJ, Vølund A, Beck-Nielsen HB. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)devidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 1996;135: 425-432
27. Rask E, Olsson T, Soderberg S, et al.; Northern Sweden Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA). Impaired incretin response after amixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 2001;24:1640-1645
28. Villareal DT, Robertson H, Bell GI, et al. TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes 2010;59:479-485
29. Smushkin G, Sathananthan M, Sathananthan A, et al. Diabetes-associated common genetic variation and its association with GLP-1 concentrations and response to exogenous GLP-1. Diabetes 2012;61:1082-1089
30. Ross SA, Brown JC, Dupŕe J. Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus. Diabetes 1977;26:525-529
31. Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001;50:609-613
32. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001;86:3717-3723
33. Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008;57:1340-1348
34. Nguyen AD, Herzog H, Sainsbury A. Neuropeptide Y and peptide YY: Important regulators of energy metabolism. Curr Opin Endocrinol Diabetes Obes 2011;18:56-60
35. Ashby D, Bloom SR. Recent progress in PYY researchdan update report for 8th NPY meeting. Peptides 2007;28:198-202
36. Derks EM, Dolan CV, Boomsma DI. Statistical power to detect genetic and environmental influences in the presence of data missing at random. Twin Res Hum Genet 2007;10:159-167
37. Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008;57:678-687
38. Martinez-Hervas S, Argente C, Garcia-Jodar J, et al. Misclassification of subjects with insulin resistance and associated cardiovascular risk factors by homeostasis model assessment index. Utility of a postprandial method based on oral glucose tolerance test. Metabolism 2011;60:740-746